Results 71 to 80 of about 99,547,245 (298)
Abstract Background Lipopolysaccharide‐responsive beige‐like anchor protein (LRBA) deficiency and cytotoxic T‐lymphocyte protein‐4 (CTLA‐4) insufficiency are recently described disorders that present with susceptibility to infections, autoimmunity, and lymphoproliferation.
Mehmet C. Catak +38 more
openaire +8 more sources
Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis
OBJECTIVE: The importance of the costimulatory molecules CD28 and CTLA-4 in the pathologic mechanism of rheumatoid arthritis (RA) has been demonstrated by genetic associations and the successful clinical application of CTLA-4Ig for the treatment of ...
Körmendy, Dezsö +6 more
core +1 more source
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai +7 more
wiley +1 more source
A hierarchically selective immunotherapeutic nanoplatform, mGls@HEV‐MTP, selectively restores macrophage immunocompetence through GLS1‐mediated restoration of glutaminolysis‐fueled anaplerosis. Concurrently, it renders Staphylococcus aureus (S. aureus) more readily recognizable to the metabolically reprogrammed macrophages, thereby facilitating ...
Weinan Yang +17 more
wiley +1 more source
Background/Aims: Gastric cancer (GC) is one of the most common and lethal varieties of cancers. Anticancer activities of anti-CTLA-4 and anti-PD-1 antibodies have been explored in different cancers, including GC.
Bin Wang, Lei Qin, Mei Ren, Hao Sun
doaj +1 more source
CTLA-4 and the genetic predisposition to autoimmunity
Abstract Due to the wide spectrum of clinical manifestations and their epidemiological dimensions, autoimmune diseases represent an important medical issue. They are the consequence of the loss of immune tolerance to autoantigens, which in turn is a result of the interaction of environmental, as well as genetic factors.
T, Dallos, L, Kovacs
openaire +2 more sources
L’immunotherapie par anticorps anti-CTLA-4, ipilimumab, est un traitement efficace du melanome metastatique utilise en monotherapie ou associe a la chimiotherapie (dacarbazine). L’effet therapeutique ne s’observe que chez 10 % a 20 % des patients, mais c’est la premiere fois qu’un medicament a un effet benefique sur la survie globale dans ce contexte ...
Caroline Robert, Christine Mateus
openaire +1 more source
Reciprocal Dosing of Anti-PD-1 and Anti-CTLA-4 Antibodies in a Staged MC38 Tumor Model.
Reciprocal Dosing of Anti-PD-1 and Anti-CTLA-4 Antibodies in a Staged MC38 Tumor Model.
Mark J. Selby (3110964) +13 more
core +1 more source
FOXP1 Knockdown Reprograms Th9 CAR‐T Cells to Overcome Antigen Escape
FOXP1 knockdown enhances Th9 CAR‐T cell function by promoting IL‐9 production, effector activation, and reduced exhaustion. Reprogrammed Th9 CAR‐T cells strengthen direct tumor killing and activate endogenous antitumor immunity through dendritic cells and CD8+ T cells, thereby suppressing both antigen‐positive and antigen‐loss tumor growth and ...
Yihan Zhu +14 more
wiley +1 more source
Additional file 1: of Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients [PDF]
Figure S1. Kaplan-Meier analysis of overall survival and progression-free survival in the anti-CTLA-4 and anti-PD-1 treated patient cohorts. Figure S2. Frequencies of major immune cell subsets in responders and non-responders to anti-CTLA-4 or anti-PD-1 ...
Zhou, Jun +29 more
core +1 more source

